Core Viewpoint - The innovation drug sector is gradually recovering, leading to valuation restoration in both A-share and Hong Kong markets, driven by regulatory optimization, stable medical insurance payment policies, and positive international clinical trial results [1] Group 1: Investment Focus - The company has concentrated its investments in hard technology, artificial intelligence, and medical fields, with representative projects in gene cell therapy, high-end ophthalmic equipment, and surgical robots, which are poised to benefit from the recovery cycle of innovative drugs [2] - In the cell therapy sector, the company invested in Yimiao Shenzhou, a local enterprise that has achieved a full-process serum-free CAR-T technology, enhancing the clinical application prospects of cell therapy products [2] Group 2: High-end Medical Devices - The company’s investment in TUPAI Medical, a domestic ophthalmic equipment platform, has led to it achieving the highest market share in domestic OCT products and entering a sales acceleration phase with its ophthalmic surgical microscope [3] - TUPAI Medical is expanding from diagnostic to therapeutic devices, establishing a foundation for an intelligent surgical platform in ophthalmology and other clinical areas [3] Group 3: Policy and Market Dynamics - The medical health sector is entering a new cycle of dual benefits from policy and market, with national emphasis on high-end medical devices and self-innovated drugs [4] - The company’s investment strategy focuses on key technological nodes and deep engagement with important enterprises, which may lead to positive impacts on its fundamentals and market image as main funds return to the innovative drug and medical technology sectors [4]

| 發行人所發行上市權證/可轉換債券的相關信息 | | | --- | --- | | 上市權證/可轉換證券名稱及代號 SHOUCHENG B2607 (5723) | | | 為享有股息權利而行使轉換權之最後 2025年7月15日 時限 | 16:30 | | 其他信息 | | | 詳情請參閱本公司2025年7月15日之公告。 | | | 發行人董事 | | | 於本公告日期，董事會包括執行董事趙天暘先生（主席）、李浩先生（副主席）、許華傑先生及劉景偉先生；非執行董事吳禮順先 | | | 生、彭吉海先生及何智恒先生；獨立非執行董事王鑫博士、張泉靈女士、諸葛文靜女士、張建偉博士及謝其潤女士。 | | EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 首程控股有限公司 | | 股份代號 | 00697 | | 多櫃檯股份代號及貨幣 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而産生或因倚賴該等內容而 引致的任何損失承擔任何責任。 （股份代號：5723） (2) 調整於 2026 年到期的 1.8 億美元 0.75%可轉換債券的轉換價 茲提述(i)首程控股有限公司（「本公司」）日期為 2025年 6月 30日、2025年 7月 9日及 2025 年 7 月 10 日的公告（統稱「該等公告」），內容有關本公司發行於 2026 年到期本金額為 1.8 億美元 0.75%的可轉換債券（「債券」）；(ii)就本公司截至 2024 年 12 月 31 日止年度的全年 業績刊發的日期為 2025 年 3 月 26 日的公告（「2024 年全年業績公告」），內容有關（其中 包括）宣派末期股息；及(iii)日期為 2025 年 4 月 30 日的投票結果公告（「2025 年投票結果公 告」），內容有關（其中包括）批准 2024 年末期股息（定義見下文）。除文義另有所指外， 本公告所用詞彙與該等公告所界定者具有相同涵義。 調整每股末期股息 誠如 2 ...

Group 1 - The core viewpoint of the articles highlights the significant advancements in the robotics sector in China, particularly with the recent procurement projects and medical achievements, indicating a shift from conceptualization to practical application of "AI + embodied intelligence" [1][2] - Zhiyuan Robotics and Yushu Technology have won a humanoid robot procurement project worth 124 million yuan from China Mobile's Hangzhou subsidiary, setting a new benchmark in the domestic robot order market [1] - The domestic SHURUI snake-arm single-port robot has successfully completed the world's first pancreatoduodenectomy, showcasing the advancements in Chinese medical robotics technology [1] Group 2 - Shoucheng Holdings is focusing on the embodied intelligence sector, with Yushu Technology being a key company of interest [1] - The company has established a strategic cluster of over 50 enterprises in the robotics field, indicating a strong commitment to developing a "national team" in robotics [1] - Shoucheng Holdings has partnered with Industrial Bank's "Xingye Life App" to launch robot products, enhancing its role as a significant promoter in the robotics industry ecosystem [1] Group 3 - The REITs projects under Shoucheng Holdings encompass various urban high-frequency space scenarios, which are ideal for the commercialization of robotics [1] - The scarcity of urban space assets and stable rental income provide a solid foundation for the trial, optimization, and replication of the company's robotics business [1] - The strategy of combining REITs with robotics positions Shoucheng Holdings favorably in the market as the robotics sector transitions from B-end to C-end applications [2]

Summary of Key Points Core Viewpoint - As of July 14, a total of 138 stocks reached their 52-week highs, indicating a strong performance in the market, with notable leaders including Green Heart Group Holdings, OK Blockchain, and Pearl River Steel Pipe [1]. Group 1: Top Performers - Green Heart Group Holdings (02999) achieved a closing price of 0.013 with a peak of 0.017, marking a 70.00% increase [1]. - OK Blockchain (01499) closed at 0.680, reaching a high of 0.690, reflecting a 48.39% rise [1]. - Pearl River Steel Pipe (01938) had a closing price of 0.335 and a peak of 0.340, resulting in a 33.33% increase [1]. Group 2: Other Notable Stocks - Weishi Jiajie (00856) saw a 32.01% increase, closing at 8.870 with a high of 11.300 [1]. - Cloud Intelligence (09678) reached a high of 520.000, closing at 510.000, which is a 20.99% increase [1]. - China Chengtong Development Group (00217) closed at 0.165 with a peak of 0.166, marking a 14.48% rise [1]. Group 3: Additional Stocks with Significant Increases - Sihuan Pharmaceutical (00460) closed at 1.380, reaching a high of 1.430, which is a 14.40% increase [1]. - Taited Pharmaceutical (03880) had a closing price of 36.950 and a peak of 37.400, reflecting a 13.85% rise [1]. - Beihai Kangcheng-B (01228) closed at 0.850 with a high of 0.960, resulting in a 12.94% increase [1].

Investment Rating - The industry investment rating is "Recommended" (maintained) [1] Core Viewpoints - The humanoid robot industry is expected to open up broader market opportunities beyond the automotive sector, with significant investment opportunities emerging as the industry transitions from "0 to 1" [16] - Recent developments include the acquisition of a controlling stake in Shangwei New Materials by Zhiyuan Robotics and the release of the Grok4 model by xAI, indicating rapid advancements in humanoid robotics [16] - The report emphasizes the importance of product iteration and business collaboration within the humanoid robotics supply chain, aiming for large-scale production and commercialization [16] Summary by Sections Industry Performance - The electric equipment sector has shown a performance increase of 27.8% over the past 12 months, outperforming the CSI 300 index, which increased by 15.8% [4] Recent Events - xAI released the Grok4 model, which demonstrated remarkable performance improvements over its predecessor Grok2, with training time increased by 100 times [5] - BYD and Hong Kong University of Science and Technology established a joint laboratory focusing on robotics and intelligent manufacturing [6] - Star Motion Era completed nearly 500 million yuan in Series A financing to enhance humanoid robot technology development [7] - Xiaomi's team secured over 100 million yuan in financing for their general-purpose robotic brain project [8] - Cloud Deep announced nearly 500 million yuan in financing aimed at expanding production lines for quadruped robots and humanoid robot technology [9] - The successful IPO of Geekplus on the Hong Kong Stock Exchange marked it as the world's first AMR warehouse robot company [10] Key Companies to Watch - Companies with core component expertise and active involvement in humanoid robotics include Sanhua Intelligent Controls, Top Group, Zhongjian Technology, Best, Zhenyu Technology, and others [16]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 首程控股有限公司 呈交日期： 2025年7月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 00697 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

Group 1 - The core viewpoint of the article is that CITIC Construction Investment Securities maintains a "buy" rating for Shoucheng Holdings, highlighting the company's increased investment in the robotics industry and its strategic partnerships to enhance smart development [1] - Shoucheng Holdings is transitioning towards becoming a comprehensive service platform in the robotics sector, focusing on integrated development [1] - Revenue projections for Shoucheng Holdings are estimated at HKD 14.63 billion, 17.07 billion, and 19.70 billion for the years 2025, 2026, and 2027 respectively, with net profits expected to be HKD 5.64 billion, 6.85 billion, and 8.03 billion for the same years [1]

Group 1 - The Chinese public REITs market is moving towards diversified and deepened development, with the approval of the first two data center REITs marking a significant step in asset diversification [1] - The data center is recognized as the "heart of computing power" driving the digital economy, with increasing demand due to advancements in technologies like AI and 5G [1] - The introduction of data center REITs provides a standardized and market-oriented exit channel, encouraging social capital participation in the sector [1] Group 2 - The strategic investment by Shoucheng Holdings reflects a deep understanding of the value of digital economy infrastructure, focusing on long-term holdings of quality assets [2] - The company is actively involved in building the Chinese REITs ecosystem, transitioning from a financial investor to a key player in infrastructure value reconstruction [3] - The investment in data center REITs not only diversifies the company's portfolio but also enhances liquidity and value, supporting the securitization of the IDC industry [3]

表格類別： 股票 狀態： 新提交 公司名稱： 首程控股有限公司 呈交日期： 2025年7月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 00697 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4 ...